P. Lippe

648 total citations
20 papers, 426 citations indexed

About

P. Lippe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, P. Lippe has authored 20 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in P. Lippe's work include Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Treatment and Pharmacology (7 papers). P. Lippe is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Treatment and Pharmacology (7 papers). P. Lippe collaborates with scholars based in Italy, Switzerland and Iran. P. Lippe's co-authors include Cristian Massacesi, Rodolfo Mattioli, Marco Rocchi, Renato Bisonni, F. Marcucci, R. Cellerino, Alberta Leon, Marco Lombardo, Salvatore Terrazzino and M. Bonsignori and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

P. Lippe

19 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Lippe Italy 11 294 172 154 55 42 20 426
Fernando Gaion Italy 8 411 1.4× 143 0.8× 199 1.3× 33 0.6× 74 1.8× 11 541
D. Mignard France 7 289 1.0× 92 0.5× 216 1.4× 33 0.6× 83 2.0× 10 442
K. Beerblock France 10 404 1.4× 134 0.8× 53 0.3× 95 1.7× 75 1.8× 22 532
Tomoyo Oguri Japan 11 183 0.6× 173 1.0× 63 0.4× 39 0.7× 34 0.8× 28 321
Masato Kataoka Japan 12 193 0.7× 200 1.2× 68 0.4× 49 0.9× 136 3.2× 51 411
Carlo Barone Italy 13 210 0.7× 200 1.2× 66 0.4× 32 0.6× 66 1.6× 20 394
Samira El Bouazzaoui Netherlands 10 159 0.5× 71 0.4× 77 0.5× 22 0.4× 89 2.1× 17 321
C. Tyler Kirkland United States 4 108 0.4× 53 0.3× 85 0.6× 22 0.4× 22 0.5× 6 292
Masaki Munakata Japan 9 217 0.7× 156 0.9× 67 0.4× 12 0.2× 92 2.2× 39 320
Atsushi Ishiguro Japan 14 207 0.7× 181 1.1× 230 1.5× 69 1.3× 162 3.9× 50 567

Countries citing papers authored by P. Lippe

Since Specialization
Citations

This map shows the geographic impact of P. Lippe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Lippe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Lippe more than expected).

Fields of papers citing papers by P. Lippe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Lippe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Lippe. The network helps show where P. Lippe may publish in the future.

Co-authorship network of co-authors of P. Lippe

This figure shows the co-authorship network connecting the top 25 collaborators of P. Lippe. A scholar is included among the top collaborators of P. Lippe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Lippe. P. Lippe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rossi, David, P. Lippe, Marco Rocchi, et al.. (2020). Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted. In Vivo. 34(5). 2687–2691. 2 indexed citations
2.
3.
Recchia, F., Giampiero Candeloro, Stefano Necozione, et al.. (2011). Long-term follow-up of a multicenter phase II study of chemo-immunotherapy in the treatment of metastatic colorectal cancer (MCC).. Journal of Clinical Oncology. 29(4_suppl). 536–536. 1 indexed citations
4.
Ruzzo, Annamaria, Emanuele Canestrari, Paolo Enrico Maltese, et al.. (2007). Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clinical Chemistry and Laboratory Medicine (CCLM). 45(7). 822–8. 56 indexed citations
5.
Mancinelli, Angelo, S D'Iddio, Renato Bisonni, et al.. (2006). Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment. Cancer Chemotherapy and Pharmacology. 60(1). 19–26. 19 indexed citations
6.
Massacesi, Cristian, Salvatore Terrazzino, F. Marcucci, et al.. (2006). Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan‐based chemotherapy. Cancer. 106(5). 1007–1016. 89 indexed citations
7.
Mattioli, Rodolfo, Cristian Massacesi, F. Recchia, et al.. (2005). High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Annals of Oncology. 16(7). 1147–1151. 40 indexed citations
8.
Lippe, P., et al.. (2005). Gemcitabine-oxaliplatin combination (GEM-OHP) in metastatic non-small cell lung cancer (NSCLC): Final results of a phase II study. Journal of Clinical Oncology. 23(16_suppl). 7293–7293. 2 indexed citations
9.
Mattioli, Rodolfo, P. Lippe, Cristian Massacesi, et al.. (2004). Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.. PubMed. 24(5B). 3257–61. 12 indexed citations
10.
Mazzanti, Paola, Cristian Massacesi, Marco Rocchi, et al.. (2003). Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 41(1). 81–89. 61 indexed citations
11.
Berardi, Rossana, Emilio Porfiri, Mario Scartozzi, et al.. (2003). Elderly Patients with Advanced Non-Small Cell Lung Cancer. Oncology. 65(3). 198–203. 32 indexed citations
12.
Massacesi, Cristian, Barbara Pistilli, P. Lippe, et al.. (2002). Predictors of Short-Term Survival and Progression to Chemotherapy in Patients With Advanced Colorectal Cancer Treated With 5-Fluorouracil-Based Regimens. American Journal of Clinical Oncology. 25(2). 140–148. 22 indexed citations
13.
Lippe, P., Rossana Berardi, Cristian Massacesi, et al.. (2002). Desmoplastic Small Round Cell Tumour: A Description of Two Cases and Review of the Literature. Oncology. 64(1). 14–17. 16 indexed citations
14.
Lippe, P., Rodolfo Mattioli, Cristian Massacesi, et al.. (2002). Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients.. PubMed. 22(2B). 1053–9. 8 indexed citations
15.
16.
Mattioli, Rodolfo, et al.. (2001). Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion.. PubMed. 21(1A). 489–92. 21 indexed citations
17.
Lippe, P., et al.. (2000). Assessing clinical benefit (CB) of chemotherapy (CT) in advanced non-small cell lung cancer elderly patients. Lung Cancer. 29(1). 34–34. 1 indexed citations
18.
Lippe, P., Nicola Battelli, Cristian Massacesi, et al.. (2000). Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study.. PubMed. 91(3-4). 53–7. 9 indexed citations
19.
Lippe, P., Diego Tummarello, D. Mari, et al.. (1999). Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study. Annals of Oncology. 10(2). 217–222. 25 indexed citations
20.
Tummarello, Diego, et al.. (1998). First line chemotherapy in patients with brain metastases from non-small and small cell lung cancer.. Oncology Reports. 5(4). 897–900. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando Gaion Breakdown of academic impact, for papers by D. Mignard Breakdown of academic impact, for papers by K. Beerblock Breakdown of academic impact, for papers by Tomoyo Oguri Breakdown of academic impact, for papers by Masato Kataoka Breakdown of academic impact, for papers by Carlo Barone Breakdown of academic impact, for papers by Samira El Bouazzaoui Breakdown of academic impact, for papers by C. Tyler Kirkland Breakdown of academic impact, for papers by Masaki Munakata Breakdown of academic impact, for papers by Atsushi Ishiguro
Rankless by CCL
2026